CEAT
Advanced Drug Technologies for the Treatment of Ovarian Cancer
The Cluster for Epigenomic and Antibody-drug conjugate (ADC) Therapeutics (CEAT) aims to advance a group of novel epigenetic drugs and ADCs to tackle ovarian cancer development and progression. CEAT is part of the Welsh Government and Industry backed SMART Expertise project part-financed by the European Regional Development Fund (ERDF)
CEAT project key facts:
4 year ERDF funded, SMART Expertise project
Total project value worth over £4.9m
Collaboration consisting of 7 Partners
Swansea University (lead), GSK, Axis Bio, Cytiva, Porvair Sciences, Bruker and Bivictrix
The CEAT project will help to prevent and treat ovarian cancer by:
Developing techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments
Advancing novel epigenetic drugs using cross cutting technology approaches.
Generating novel ADCs that are effective against ovarian cancer
The CEAT Project Launch took place in Swansea University on 4th February 2019
Left to right top row:
Anna Moberg, GE Healthcare; Lydia Powell, Swansea University; Marcos Quintella, Swansea University; Steve Conlan, Swansea University; Emenike Onyido, SU; Jay Jefferies, Welsh Government; Lewis Francis, Swansea University; Amy Johnson, Porvair Sciences; Catherine Maguire, Axis Bio;
Left to right bottom row:
David James, Swansea University; Jenny Worthington, Axis Bio; Tim Fagge, GE Healthcare; Deya Gonzalez, Swansea University; Zoe Coombes, Swansea University; Julia Davies, Porvair Sciences; Nicky Harker, GlaxoSmithKline.
